Pure Bioscience Inc (PURE) Financial Statements (2024 and earlier)

Company Profile

Business Address 771 JAMACHA ROAD #512
EL CAJON, CA 92019
State of Incorp. DE
Fiscal Year End July 31
Industry (SIC) 289 - Miscellaneous Chemical Products (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

4/30/2024
MRQ
1/31/2024
MRQ
7/31/2023
7/31/2022
7/31/2021
7/31/2020
7/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5571,0953,3912,3903,839398
Cash and cash equivalents5571,0953,3912,3903,839398
Receivables1712852013681,089373
Inventory, net of allowances, customer advances and progress billings7488179332547177
Inventory7488179332547177
Prepaid expense626118321618
Other undisclosed current assets757575757575
Total current assets:9391,6043,8643,1975,5661,041
Noncurrent Assets
Property, plant and equipment147221620740316362
Intangible assets, net (including goodwill)    366441529
Intangible assets, net (excluding goodwill)    366441529
Total noncurrent assets:1472216201,106757891
TOTAL ASSETS:1,0861,8254,4844,3036,3231,932
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5455325757311,512738
Accounts payable4094224885931,344553
Accrued liabilities13611087138168185
Debt    239  
Total current liabilities:5455325759701,512738
Noncurrent Liabilities
Long-term debt and lease obligation  1,021    
Long-term debt, excluding current maturities  1,021    
Liabilities, other than long-term debt      4
Deferred rent credit      4
Other undisclosed noncurrent liabilities1,862     
Total noncurrent liabilities:1,8621,021   4
Total liabilities:2,4071,5535759701,512742
Equity
Equity, attributable to parent(1,321)2723,9093,3334,8111,190
Common stock1,1191,1191,114873871768
Additional paid in capital132,542132,398132,079128,253127,414123,900
Accumulated deficit(134,982)(133,245)(129,284)(125,793)(123,474)(123,478)
Total equity:(1,321)2723,9093,3334,8111,190
TOTAL LIABILITIES AND EQUITY:1,0861,8254,4844,3036,3231,932

Income Statement (P&L) ($ in thousands)

4/30/2024
TTM
1/31/2024
TTM
7/31/2023
7/31/2022
7/31/2021
7/31/2020
7/31/2019
Revenues2,0511,8711,8133,6986,9171,909
Cost of revenue
(Cost of Goods and Services Sold)
(921)(906)(853)(1,852)(2,896)(728)
Other undisclosed gross profit6640229  
Gross profit:1,1369711,0002,0754,0211,181
Operating expenses(4,710)(4,914)(4,724)(4,386)(4,017)(7,498)
Other undisclosed operating income      728
Operating income (loss):(3,574)(3,943)(3,724)(2,311)4(5,589)
Nonoperating income (expense)(71)(18)233(8)5(965)
Other nonoperating income (expense)1(4) (4)51
Interest and debt expense(72)(14)239(4)(5)(6)
Income (loss) from continuing operations:(3,717)(3,975)(3,252)(2,323)4(6,560)
Income (loss) before gain (loss) on sale of properties:(3,252)(2,323)4(6,560)
Net income (loss):(3,717)(3,975)(3,252)(2,323)4(6,560)
Other undisclosed net income (loss) attributable to parent7214(239)4 6
Net income (loss) available to common stockholders, diluted:(3,645)(3,961)(3,491)(2,319)4(6,554)

Comprehensive Income ($ in thousands)

4/30/2024
TTM
1/31/2024
TTM
7/31/2023
7/31/2022
7/31/2021
7/31/2020
7/31/2019
Net income (loss):(3,717)(3,975)(3,252)(2,323)4(6,560)
Comprehensive income (loss), net of tax, attributable to parent:(3,717)(3,975)(3,252)(2,323)4(6,560)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: